Immutep Ltd Adr Stock Net Income
| IMMP Stock | USD 3.08 0.10 3.14% |
As of the 27th of January, Immutep retains the Downside Deviation of 3.52, market risk adjusted performance of 1.09, and Risk Adjusted Performance of 0.1334. Immutep technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from Immutep's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Immutep's valuation are summarized below:Immutep Ltd ADR does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immutep. If investors know Immutep will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immutep listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immutep Ltd ADR is measured differently than its book value, which is the value of Immutep that is recorded on the company's balance sheet. Investors also form their own opinion of Immutep's value that differs from its market value or its book value, called intrinsic value, which is Immutep's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immutep's market value can be influenced by many factors that don't directly affect Immutep's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immutep's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immutep is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immutep's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immutep 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Immutep's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Immutep.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Immutep on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Immutep Ltd ADR or generate 0.0% return on investment in Immutep over 90 days. Immutep is related to or competes with ProQR Therapeutics, Candel Therapeutics, Allogene Therapeutics, Capricor Therapeutics, Editas Medicine, Mereo BioPharma, and Vanda Pharmaceuticals. Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products More
Immutep Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Immutep's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Immutep Ltd ADR upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.52 | |||
| Information Ratio | 0.1539 | |||
| Maximum Drawdown | 31.54 | |||
| Value At Risk | (5.41) | |||
| Potential Upside | 7.41 |
Immutep Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immutep's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Immutep's standard deviation. In reality, there are many statistical measures that can use Immutep historical prices to predict the future Immutep's volatility.| Risk Adjusted Performance | 0.1334 | |||
| Jensen Alpha | 0.787 | |||
| Total Risk Alpha | 0.3693 | |||
| Sortino Ratio | 0.2189 | |||
| Treynor Ratio | 1.08 |
Immutep January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1334 | |||
| Market Risk Adjusted Performance | 1.09 | |||
| Mean Deviation | 3.47 | |||
| Semi Deviation | 2.99 | |||
| Downside Deviation | 3.52 | |||
| Coefficient Of Variation | 589.27 | |||
| Standard Deviation | 5.01 | |||
| Variance | 25.13 | |||
| Information Ratio | 0.1539 | |||
| Jensen Alpha | 0.787 | |||
| Total Risk Alpha | 0.3693 | |||
| Sortino Ratio | 0.2189 | |||
| Treynor Ratio | 1.08 | |||
| Maximum Drawdown | 31.54 | |||
| Value At Risk | (5.41) | |||
| Potential Upside | 7.41 | |||
| Downside Variance | 12.42 | |||
| Semi Variance | 8.95 | |||
| Expected Short fall | (4.22) | |||
| Skewness | 2.18 | |||
| Kurtosis | 9.76 |
Immutep Ltd ADR Backtested Returns
Immutep appears to be very risky, given 3 months investment horizon. Immutep Ltd ADR holds Efficiency (Sharpe) Ratio of 0.17, which attests that the entity had a 0.17 % return per unit of risk over the last 3 months. By evaluating Immutep's technical indicators, you can evaluate if the expected return of 0.85% is justified by implied risk. Please utilize Immutep's Market Risk Adjusted Performance of 1.09, risk adjusted performance of 0.1334, and Downside Deviation of 3.52 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Immutep holds a performance score of 13. The company retains a Market Volatility (i.e., Beta) of 0.78, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Immutep's returns are expected to increase less than the market. However, during the bear market, the loss of holding Immutep is expected to be smaller as well. Please check Immutep's semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Immutep's current trending patterns will revert.
Auto-correlation | 0.05 |
Virtually no predictability
Immutep Ltd ADR has virtually no predictability. Overlapping area represents the amount of predictability between Immutep time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Immutep Ltd ADR price movement. The serial correlation of 0.05 indicates that only as little as 5.0% of current Immutep price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.05 | |
| Spearman Rank Test | -0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Immutep Ltd ADR reported net income of (61.43 Million). This is 118.0% lower than that of the Biotechnology sector and 187.71% lower than that of the Health Care industry. The net income for all United States stocks is 110.76% higher than that of the company.
Immutep Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immutep's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immutep could also be used in its relative valuation, which is a method of valuing Immutep by comparing valuation metrics of similar companies.Immutep is currently under evaluation in net income category among its peers.
Immutep Fundamentals
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (20.35) % | ||||
| Current Valuation | 375.52 M | ||||
| Shares Outstanding | 147.19 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 2.16 % | ||||
| Number Of Shares Shorted | 4.9 M | ||||
| Price To Earning | (152.55) X | ||||
| Price To Book | 4.75 X | ||||
| Price To Sales | 92.80 X | ||||
| Revenue | 5.04 M | ||||
| Gross Profit | (56.37 M) | ||||
| EBITDA | (62.88 M) | ||||
| Net Income | (61.43 M) | ||||
| Cash And Equivalents | 80 M | ||||
| Cash Per Share | 0.92 X | ||||
| Total Debt | 1.63 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.16 X | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (62.05 M) | ||||
| Short Ratio | 2.82 X | ||||
| Earnings Per Share | (0.48) X | ||||
| Target Price | 9.5 | ||||
| Beta | 1.73 | ||||
| Market Capitalization | 468.07 M | ||||
| Total Asset | 156.98 M | ||||
| Retained Earnings | (444.08 M) | ||||
| Working Capital | 180.86 M | ||||
| Current Asset | 1.89 M | ||||
| Current Liabilities | 1.04 M | ||||
| Net Asset | 156.98 M |
About Immutep Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immutep Ltd ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immutep using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immutep Ltd ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Immutep
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immutep position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immutep will appreciate offsetting losses from the drop in the long position's value.Moving together with Immutep Stock
Moving against Immutep Stock
| 0.76 | PPBT | Purple Biotech | PairCorr |
| 0.5 | MREO | Mereo BioPharma Group | PairCorr |
| 0.45 | SLN | Silence Therapeutics PLC Downward Rally | PairCorr |
| 0.45 | COEP | Coeptis Therapeutics | PairCorr |
| 0.41 | FSTF | First State Financial | PairCorr |
The ability to find closely correlated positions to Immutep could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immutep when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immutep - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immutep Ltd ADR to buy it.
The correlation of Immutep is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immutep moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immutep Ltd ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immutep can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Immutep Stock Analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.